NEW YORK (GenomeWeb) – GeneNews announced today that it has signed a deal to offer three of its cancer diagnostic tests through healthcare services management firm NueHealth.

Under the terms of the three-year arrangement, GeneNews' blood-based ColonSentry, earlyCDT-Lung and Prostate Health Index tests — which are designed for early patient risk stratification in colorectal, lung, and prostate cancers, respectively — will be offered to patients at NueHealth's provider-owned care centers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.